Beam’s Breakthrough: Revolutionizing Genetic Medicine?
Beam Therapeutics Inc., a leading biotechnology company specializing in precision genetic medicines through base editing, has recently made a significant announcement. In August, the company initiated treatment for its first patient with BEAM-201, a quadruplex-edited allogeneic CAR-T cell investigational therapy. This therapy is currently under evaluation in a Phase 1/2 clinical trial aimed at treating […]
Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease
CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the first patient has been enrolled in the company’s BEACON trial. BEACON is an open-label, single-arm, multicenter, Phase 1/2 clinical trial designed to evaluate the safety and efficacy of BEAM-101 in […]